CpG 1018: A Toll-Like Receptor 9 Agonist Adjuvant Advancing Vaccine Technology

I. Abstract

CpG 1018, a synthetic oligodeoxynucleotide (ODN) functioning as a potent Toll-Like Receptor 9 (TLR9) agonist, represents a significant advancement in vaccine adjuvant technology. Developed by Dynavax Technologies, this 22-mer ODN is designed to mimic bacterial DNA, thereby stimulating a robust innate immune response characterized by the production of Th1-polarizing cytokines and the activation of both humoral and cellular immunity. Its primary mechanism involves the engagement of TLR9 on plasmacytoid dendritic cells and B cells, leading to enhanced antigen presentation and a stronger, more durable immune response compared to traditional adjuvants like alum. The most prominent application of CpG 1018 is as the adjuvant in HEPLISAV-B®, an FDA and EMA-approved hepatitis B vaccine. Clinical trials of HEPLISAV-B® have consistently demonstrated superior seroprotection rates and a more rapid onset of protection, particularly in populations that respond suboptimally to conventional hepatitis B vaccines, such as older adults and individuals with diabetes. Beyond HEPLISAV-B®, CpG 1018 is a critical component in several investigational vaccines targeting shingles (Z-1018), plague (rF1V), pandemic influenza (H5N1), and Lyme disease, showcasing its versatility. Furthermore, its immunomodulatory properties are being explored in a novel therapeutic context for Alzheimer's disease. The well-defined mechanism of action, established safety profile from extensive clinical use, and demonstrated ability to enhance immunogenicity position CpG 1018 as a key enabler of next-generation vaccines and immunotherapies, addressing significant unmet medical needs across a spectrum of infectious and non-infectious diseases.

II. Introduction: The Imperative for Advanced Vaccine Adjuvants

A. The Role of Adjuvants in Modern Vaccinology

Vaccine adjuvants are critical components that enhance the immunogenicity of antigens, thereby improving the efficacy of vaccines. For decades, aluminum salts (alum) have been the most widely used adjuvants in human vaccines.[1] Their development was largely empirical, and while they have a long history of safe use, it has become evident that alum-based adjuvants are suboptimal for certain antigens or in specific populations, such as the elderly or immunocompromised individuals, who may exhibit diminished immune responses.[1] Traditional adjuvants like alum primarily induce a Th2-biased humoral immune response, which may not be sufficient for protection against all pathogens, particularly those requiring strong cell-mediated immunity (Th1 responses) for clearance.[3]

The evolution of adjuvant science reflects a significant paradigm shift, moving from serendipitous discovery, as was the case with alum, towards a more rational, mechanism-based design approach.[1] This modern strategy is rooted in a deeper understanding of innate immunity and its role in shaping adaptive immune responses. Adjuvants like CpG 1018 are products of this rational design, targeting specific pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), to elicit tailored and more potent immune activation.[4] This targeted approach allows for more predictable adjuvant effects and the ability to specifically direct the nature of the immune response (e.g., Th1 versus Th2), which is crucial for developing effective vaccines against a diverse range of pathogens and diseases. The demand for adjuvants capable of inducing robust Th1 responses, alongside strong antibody production, has driven the exploration of novel immunostimulatory molecules.[4]

B. Introduction to CpG Oligodeoxynucleotides (ODNs) as Immunostimulants

CpG oligodeoxynucleotides (ODNs) are short synthetic DNA molecules containing unmethylated cytosine-phosphate-guanine (CpG) motifs. These motifs are characteristic of microbial DNA and are recognized as pathogen-associated molecular patterns (PAMPs) by the vertebrate innate immune system.[5] The immune system has evolved to detect these CpG motifs as danger signals, triggering a rapid and robust defense response.

CpG ODNs are classified into different types (e.g., Class A, Class B, Class C) based on their structural features and the specific immune responses they induce.[5] Class B CpG ODNs, to which CpG 1018 belongs, are potent activators of B cells and stimulate the maturation of plasmacytoid dendritic cells (pDCs) to secrete Th1-polarizing cytokines.[5] The discovery of the immunostimulatory properties of CpG ODNs led to their investigation as potential vaccine adjuvants, capable of significantly enhancing both innate and adaptive immune responses to co-administered antigens.

C. CpG 1018: A Promising TLR9 Agonist Adjuvant

CpG 1018 is a proprietary Class B CpG ODN developed by Dynavax Technologies.[1] It is designed to act as a potent agonist for Toll-like receptor 9 (TLR9), thereby harnessing the power of the innate immune system to augment vaccine efficacy. This report provides a comprehensive review of CpG 1018, detailing its molecular characteristics, mechanism of action, the development and success of HEPLISAV-B®, its applications in other investigational vaccines and therapeutics, regulatory status, and its overall impact on the field of vaccinology.

III. CpG 1018: Molecular Characteristics and Mechanism of Action

A. Structure and Synthesis of CpG 1018

CpG 1018 is a synthetic, 22-mer oligodeoxynucleotide with the specific sequence 5′-TGACTGTGAACGTTCGAGATGA-3′.[1] A critical structural feature is its phosphorothioate backbone, where a non-bridging oxygen atom in the phosphate group is replaced by a sulfur atom. This modification confers resistance to degradation by cellular nucleases, thereby increasing its in vivo stability and duration of action.[5] The sequence contains specific CpG motifs that are recognized by TLR9 and are active in both rodents and primates, including humans, facilitating translational research.[1] The CAS number for CpG 1018 is 937402-51-2.[5] For preclinical research, high-quality preparations such as ODN 1018 VacciGrade™ are available, ensuring sterility and low endotoxin levels, which are crucial for reliable in vivo studies.[5]

Table 1: Overview of CpG 1018 Adjuvant

Property	Description
Sequence	5′-TGACTGTGAACGTTCGAGATGA-3′ (22-mer, phosphorothioate backbone) 5
Type	Class B CpG Oligodeoxynucleotide (ODN) 5
Target Receptor	Toll-like Receptor 9 (TLR9) 4
Key Immunological Effects	Induction of Th1-biased immune responses, activation of pDCs and B cells, enhanced antibody production, stimulation of CD4+ and CD8+ T cells, generation of memory responses 4

The careful design and synthesis of CpG 1018, particularly the phosphorothioate modification, are essential for its function as an effective adjuvant. While this modification enhances stability, it can also, in some ODN contexts, lead to non-specific protein binding or off-target effects if the ODN is not meticulously designed and purified. The availability of high-purity grades like VacciGrade™, with stringent quality controls for sterility and endotoxin content, underscores the importance of minimizing such confounders in preclinical research to ensure the data accurately reflects the specific TLR9-mediated activity and supports successful clinical translation.[5]

B. Toll-Like Receptor 9 (TLR9) Agonism

The primary mechanism of action of CpG 1018 involves its interaction with Toll-like receptor 9 (TLR9).[4] TLR9 is an endosomal pattern recognition receptor predominantly expressed by plasmacytoid dendritic cells (pDCs) and B lymphocytes in humans.[5] It plays a crucial role in the innate immune system by recognizing unmethylated CpG motifs present in bacterial and viral DNA, distinguishing them from the methylated CpG sequences typically found in vertebrate DNA.[5] Upon endocytosis of CpG 1018, it traffics to the endosomal compartment where it binds to TLR9. This binding initiates a signaling cascade, primarily through the MyD88-dependent pathway, leading to the activation of transcription factors such as NF-κB and IRF7.[5]

C. Immunological Consequences of TLR9 Activation by CpG 1018

The activation of TLR9 by CpG 1018 triggers a cascade of immunological events that collectively enhance and shape the adaptive immune response to co-administered antigens:

1. Activation of pDCs and B cells: Direct stimulation of pDCs leads to the production of large amounts of type I interferons (IFN-α/β), which have broad antiviral and immunomodulatory effects. B cell activation through TLR9 promotes their proliferation, differentiation into antibody-secreting plasma cells, and enhanced antigen presentation capabilities.[5]
2. Induction of Th1-polarizing cytokines: Activated pDCs and other antigen-presenting cells (APCs) upregulate the production of cytokines such as Interleukin-12 (IL-12) and IFN-γ.[4] IL-12 is a key cytokine that drives the differentiation of naive CD4+ T helper cells into Th1 cells. IFN-γ, produced by Th1 cells and NK cells, further amplifies the Th1 response and activates macrophages.[6]
3. Stimulation of T cell populations: The Th1-polarizing environment fostered by CpG 1018 promotes the development of robust CD4+ Th1 responses and supports the generation and activation of cytotoxic T lymphocytes (CTLs, CD8+ T cells).[4] CTLs are critical for eliminating cells infected with viruses or other intracellular pathogens.
4. Enhanced antibody production and memory: CpG 1018 significantly boosts antigen-specific antibody titers and promotes the generation of long-lived plasma cells and memory B cells, contributing to durable immunity.[1] The Th1 environment also influences antibody isotype switching, favoring the production of opsonizing and complement-fixing antibodies.
5. Th1 Bias: A hallmark of CpG 1018 adjuvanticity is its strong bias towards the development of Th1 helper T cells.[3] This is particularly advantageous for vaccines targeting viruses and intracellular bacteria, where cell-mediated immunity plays a pivotal protective role.

The direct engagement of TLR9 by CpG 1018 is the fundamental cause of its characteristic Th1-skewing immunomodulatory effects. This specific interaction initiates a well-defined signaling pathway, leading to a cytokine milieu (rich in IL-12 and IFN-γ) that preferentially supports Th1 cell differentiation and function. This Th1 bias is mechanistically linked to the observed enhancement in cellular immunity, including CTL activation, and the production of antibody isotypes effective against viral and intracellular pathogens, as demonstrated in various vaccine applications.

D. Preclinical Pharmacology, Pharmacokinetics, and Toxicology Overview

Preclinical studies with CpG 1018, often in conjunction with antigens like Hepatitis B surface antigen (HBsAg), consistently demonstrated superior immunogenicity compared to alum-adjuvanted formulations. These studies showed that CpG 1018 induced substantially higher antibody titers.[1] The pharmacokinetic profile of oligodeoxynucleotides like CpG 1018 is influenced by their phosphorothioate backbone, which enhances resistance to nuclease degradation, leading to improved in vivo stability and a longer half-life compared to unmodified ODNs.[5] Preclinical toxicology studies have generally indicated a favorable safety profile for CpG 1018, with local injection site reactions being the most common observation, and systemic toxicity being low at adjuvant doses.[1] InvivoGen's ODN 1018 VacciGrade™, designed for preclinical research, undergoes rigorous quality control for sterility and endotoxin levels, ensuring the reliability of in vivo experimental outcomes.[5]

IV. Development and Application of CpG 1018 in HEPLISAV-B®

A. HEPLISAV-B®: The First FDA-Approved CpG 1018-Adjuvanted Vaccine

1. Rationale for Development

The development of HEPLISAV-B® was driven by the recognized need for a more immunogenic hepatitis B vaccine, particularly for populations known to respond suboptimally to conventional alum-adjuvanted vaccines. These groups include older adults, individuals with diabetes mellitus, and patients with chronic kidney disease, including those on hemodialysis.[1] Traditional hepatitis B vaccines often require a three-dose schedule over six months and may still fail to elicit protective antibody levels in a significant proportion of these harder-to-immunize individuals. CpG 1018 was selected as the adjuvant for HEPLISAV-B® with the aim of inducing a more rapid, robust, and durable immune response to the hepatitis B surface antigen (HBsAg).[1]

2. Clinical Trial Program

The clinical development of HEPLISAV-B® involved several large-scale Phase 3 trials, notably HBV-23 (NCT02179742), HBV-17, and HBV-10, which collectively enrolled thousands of adult participants.[18] These trials were designed to compare the immunogenicity and safety of a two-dose regimen of HEPLISAV-B® (administered at 0 and 1 month) with a three-dose regimen of a licensed alum-adjuvanted hepatitis B vaccine, Engerix-B® (administered at 0, 1, and 6 months). The primary immunogenicity endpoint was the seroprotection rate (SPR), defined as the proportion of subjects achieving an anti-HBs antibody concentration of ≥10 mIU/mL.

Key findings from these trials consistently demonstrated the superiority of HEPLISAV-B®:

• Study 1 (Adults 18-55 years, NCT00435812): At Week 12 (post-HEPLISAV-B® second dose) and Week 28 (post-Engerix-B® third dose), the SPR was 95% for HEPLISAV-B® compared to 81.3% for Engerix-B®. HEPLISAV-B® was shown to be non-inferior.[18]
• Study 2 (Adults 40-70 years): At Week 12 (HEPLISAV-B®) and Week 32 (Engerix-B®), the SPR was 90.1% for HEPLISAV-B® versus 70.5% for Engerix-B®, demonstrating both non-inferiority and statistical superiority of HEPLISAV-B®.[18]
• Study 3 (Adults 18-70 years, including individuals with type 2 diabetes): In the subgroup with type 2 diabetes, the SPR at Week 28 was 90.0% for HEPLISAV-B® versus 65.1% for Engerix-B®. In the overall study population, the SPR at Week 24 for HEPLISAV-B® was 95.4% compared to 81.3% at Week 28 for Engerix-B®. Both comparisons demonstrated non-inferiority and statistical superiority for HEPLISAV-B®.[18]

Across all pivotal trials, HEPLISAV-B® achieved higher seroprotection rates, often with statistical significance, and in a shorter timeframe (two doses over one month) compared to the conventional three-dose, six-month regimen of Engerix-B®.[18]

Table 2: HEPLISAV-B® - Key Clinical Trial Efficacy Data (Seroprotection Rates vs. Engerix-B®)

Study Population (Age, Specific Conditions)	HEPLISAV-B® SPR (%) (Timepoint)	Engerix-B® SPR (%) (Timepoint)	Key Finding (Difference in SPRs, 95% CI)	Reference(s)
Adults 18-55 years	95 (Week 12)	81.3 (Week 28)	13.7% (10.4, 17.5)	18
Adults 40-70 years	90.1 (Week 12)	70.5 (Week 32)	19.6% (14.8, 24.7)	18
Adults 18-70 years (Type 2 Diabetes)	90.0 (Week 28)	65.1 (Week 28)	24.9% (16.6, 33.3)	18
Adults 18-70 years (Overall from Study 3)	95.4 (Week 24)	81.3 (Week 28)	14.2% (12.0, 16.5)	18

3. Safety and Tolerability Profile of HEPLISAV-B®

The safety of HEPLISAV-B® was extensively evaluated in the clinical trial program, involving over 9,500 individuals who received at least one dose.[18]

• Local Reactions: The most frequently reported local adverse reaction was injection site pain, occurring in 9% to 39% of HEPLISAV-B® recipients. Other common local reactions included erythema (redness) and swelling at the injection site.[18]
• Systemic Reactions: Common systemic adverse reactions included fatigue (10%-17%) and headache (5%-17%). Myalgia and malaise were also reported. Fever (temperature ≥38∘C) was generally reported in less than 2% of recipients.[18]
• Serious Adverse Events (SAEs): The overall incidence of SAEs was similar between the HEPLISAV-B® and Engerix-B® groups. In Study 3, a numerical imbalance in acute myocardial infarction (AMI) events was observed (0.25% in HEPLISAV-B® group vs. 0.04% in Engerix-B® group). However, all subjects who experienced an AMI had multiple pre-existing cardiovascular risk factors, and an independent cardiovascular safety assessment committee concluded that the data did not support a causal relationship between HEPLISAV-B® administration and AMI.[18]
• Potentially Immune-Mediated Adverse Events: The incidence of new-onset potentially immune-mediated adverse events was low and comparable between the HEPLISAV-B® and Engerix-B® groups. An external, blinded expert panel adjudicated these events and found none to be related to vaccination.[18]
• Postmarketing Experience: Adverse reactions identified during post-approval use of HEPLISAV-B® include anaphylaxis and other hypersensitivity reactions, dizziness, paresthesia, gastrointestinal symptoms (nausea, diarrhea, abdominal pain), and injection site pruritus.[18]

4. Approved Indications and Dosage

HEPLISAV-B® is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.[4] The vaccine is administered as a two-dose series, with 0.5 mL given intramuscularly at 0 and 1 month.[18] Dynavax has also sought label expansion for the use of HEPLISAV-B® in adults on hemodialysis, a population known for poor response to conventional hepatitis B vaccines.[15]

The successful development and regulatory approval of HEPLISAV-B® served as a crucial validation for CpG 1018 as a safe and effective adjuvant in a large-scale human clinical program. The ability to achieve superior immunogenicity, especially in challenging populations like older adults and individuals with diabetes, with a more convenient two-dose, one-month schedule, marked a significant advancement in hepatitis B prevention. This success has undoubtedly bolstered confidence in the broader applicability of CpG 1018 for other vaccine candidates, establishing a strong precedent for its use in enhancing immune responses while maintaining an acceptable safety profile.

V. CpG 1018 in Other Vaccine Development Programs (Pipeline)

The demonstrated success of CpG 1018 in HEPLISAV-B® has spurred its inclusion in a diverse range of investigational vaccine programs targeting various infectious diseases and even non-infectious conditions like Alzheimer's disease.

A. COVID-19 Vaccines

CpG 1018 has been utilized as an adjuvant in several COVID-19 vaccine candidates, often in combination with alum, to enhance the immune response to SARS-CoV-2 antigens.[16]

• CORBEVAX™ (Biological E): This protein subunit vaccine, combining a SARS-CoV-2 receptor-binding domain (RBD) antigen with CpG 1018 and alum, received Emergency Use Approval in India in December 2021. Dynavax has a commercial supply agreement with Biological E for CpG 1018.[16]
• VLA2001 (Valneva): An inactivated whole virus SARS-CoV-2 vaccine also adjuvanted with CpG 1018 and alum. This vaccine received a positive opinion from the EMA's CHMP and conditional marketing authorization from the UK's MHRA.[17] The rationale for using CpG 1018 in these vaccines was to elicit a stronger and more Th1-biased immune response, potentially leading to higher neutralizing antibody titers and improved cellular immunity against SARS-CoV-2.[16]

B. Shingles Vaccine Program (Z-1018)

Dynavax is developing Z-1018, an investigational vaccine candidate for the prevention of shingles (herpes zoster) in adults aged 50 years and older. Z-1018 combines the varicella-zoster virus (VZV) glycoprotein E (gE) antigen with CpG 1018, with or without alum.25

A Phase 1/2 clinical trial (NCT05245838) is currently underway to evaluate the safety, tolerability, and immunogenicity of Z-1018 compared to the licensed shingles vaccine, Shingrix®. Part 1 of this trial, a dose-escalation study in adults aged 50-69, completed enrollment in Q4 2024, with top-line immunogenicity and safety data anticipated in Q3 2025. Based on these results, Dynavax plans to advance a selected formulation into Part 2 of the study, focusing on adults over 70 years, to establish clinical proof-of-concept.25 The goal is to develop a differentiated shingles vaccine, potentially offering an improved tolerability profile or a more convenient dosing schedule compared to existing options.29

C. Plague Vaccine Program (rF1V + CpG 1018)

In collaboration with the U.S. Department of Defense (DoD), Dynavax is developing a plague vaccine candidate that combines the DoD's recombinant F1-V fusion protein antigen (rF1V) with CpG 1018 adjuvant.[25] This program is fully funded by the DoD. A Phase 2 clinical trial is expected to initiate in the third quarter of 2025, supported by a new agreement providing approximately $30 million through the first half of 2027 for continued clinical and manufacturing activities.[25] The primary aim is to enhance the protective efficacy of the rF1V antigen, potentially allowing for fewer doses or a shorter immunization schedule to protect against this high-threat pathogen.[33]

D. Pandemic Influenza Adjuvant Program (H5N1 + CpG 1018)

Leveraging its experience as a supplier of CpG 1018 for COVID-19 vaccines, Dynavax aims to generate clinical proof-of-concept for CpG 1018-adjuvanted pandemic influenza vaccines.[10] A Phase 1/2 randomized, active-controlled study is planned to initiate in the second quarter of 2025. This study will evaluate the safety and immunogenicity of an investigational H5N1 influenza vaccine adjuvanted with CpG 1018 in adults aged 18 to 49 years.[25] Preclinical research in aged mice has already indicated that CpG 1018 can significantly enhance the immunogenicity and protective efficacy of influenza vaccines in this vulnerable population.[10]

E. Lyme Disease Vaccine Program

Dynavax is developing an investigational multivalent protein subunit vaccine candidate adjuvanted with CpG 1018 for the prevention of Lyme disease, a common vector-borne illness.[25] This program has advanced into Investigational New Drug (IND)-enabling studies, with clinical development anticipated to begin in 2027.[25] Dynavax believes that the inclusion of CpG 1018 could lead to a differentiated, best-in-class Lyme disease vaccine, potentially offering improved durability of protection or requiring fewer doses.[25]

F. Alzheimer's Disease (AD) Therapy (CpG 1018 monotherapy)

A particularly novel application of CpG 1018 is its investigation as a standalone immunomodulatory therapy for early Alzheimer's disease. A clinical trial (NCT05606341) is underway to assess the impact of CpG 1018 monotherapy in this patient population.[5] The rationale stems from the understanding that TLR9 is an important regulator of microglial cells in the central nervous system (CNS). The hypothesis is that CpG 1018, by activating microglial TLR9, could stimulate beneficial microglial functions, such as the clearance of amyloid-β plaques and a reduction in neuroinflammation, thereby potentially slowing or halting disease progression.[5]

This therapeutic strategy diverges significantly from the traditional role of CpG 1018 as a vaccine adjuvant, where it enhances the response to a co-administered antigen. In the context of Alzheimer's disease, CpG 1018 is being explored for its direct immunomodulatory effects on innate immune cells within the CNS. The goal is not to augment an antigen-specific adaptive immune response, but rather to modulate microglial phenotypes towards a more neuroprotective state—for instance, by promoting phagocytosis of pathological protein aggregates and reducing the production of detrimental pro-inflammatory mediators. This represents an innovative expansion of CpG 1018's therapeutic potential beyond conventional vaccinology.

Table 3: CpG 1018 Adjuvanted Vaccines and Therapeutics in Clinical Development (Pipeline)

Vaccine/Therapeutic Name/Target	Indication	Development Phase	Key Collaborator(s)	Brief Status/Key Findings (NCT Number if available)
HEPLISAV-B®	Hepatitis B	Approved	Dynavax	FDA, EMA, MHRA approved for adults ≥18 years. Superior SPR vs. Engerix-B. 4
CORBEVAX™	COVID-19	Approved (EUA)	Biological E	Protein subunit + CpG 1018/Alum. EUA in India. 16
VLA2001	COVID-19	Approved (Conditional)	Valneva	Inactivated whole virus + CpG 1018/Alum. CMA in UK, Positive CHMP opinion. 21
Z-1018	Shingles	Phase 1/2	Dynavax	gE antigen + CpG 1018 +/- Alum. Part 1 (NCT05245838) enrollment complete, data Q3 2025. Part 2 planned for >70 yrs. 25
rF1V + CpG 1018	Plague	Phase 2 (planned)	U.S. Dept. of Defense	Fully funded by DoD. Phase 2 trial expected to initiate Q3 2025. 25
H5N1 Vaccine + CpG 1018	Pandemic Influenza	Phase 1/2 (planned)	Dynavax	Investigational H5N1 vaccine + CpG 1018. Phase 1/2 study expected to initiate Q2 2025. 25
Lyme Disease Vaccine	Lyme Disease	IND-enabling	Dynavax	Multivalent protein subunit + CpG 1018. Clinical development planned for 2027. 25
CpG 1018 Monotherapy	Early Alzheimer's Disease	Phase 1	Dynavax/Collaborators	Investigating CpG 1018 alone. NCT05606341. 5

VI. Regulatory Landscape and Approvals

A. HEPLISAV-B® Approvals

HEPLISAV-B® has achieved significant regulatory milestones, underscoring the successful translation of CpG 1018 technology into a licensed product.

• U.S. Food and Drug Administration (FDA): Approved in November 2017 for the prevention of hepatitis B in adults 18 years of age and older.[4]
• European Commission (EMA): Granted marketing authorization for use in the European Union.[16]
• UK Medicines and Healthcare products Regulatory Agency (MHRA): Granted Marketing Authorization in February 2023.[15]

B. Approvals/Authorizations for Other CpG 1018-Adjuvanted Vaccines

The utility of CpG 1018 as an adjuvant has been further recognized through authorizations for COVID-19 vaccines:

• CORBEVAX™ (Biological E): Received Emergency Use Approval from the Drugs Controller General of India (DCGI) in December 2021.[16]
• VLA2001 (Valneva): Received Conditional Marketing Authorization from the UK MHRA and a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP).[21]

C. Regulatory Designations

The available research snippets do not explicitly state that CpG 1018 itself or HEPLISAV-B® have received specific regulatory designations such as Fast Track, Orphan Drug, Breakthrough Therapy, or PRIME from the FDA or EMA.[15] While partner companies like Valneva have received such designations for other vaccine candidates (e.g., VLA1553 for Chikungunya received Fast Track and PRIME status), these do not directly apply to CpG 1018-containing products unless specified.[23]

The successful navigation of stringent regulatory reviews by agencies like the FDA and EMA for HEPLISAV-B® is a testament to the robustness of the clinical data supporting CpG 1018's efficacy and safety. This established regulatory precedent is invaluable. With a well-documented safety and efficacy profile for the adjuvant component, subsequent vaccine candidates utilizing CpG 1018 may encounter a more streamlined regulatory assessment, provided the antigen-specific data is compelling. This prior validation can reduce uncertainties for regulatory bodies when evaluating new combinations involving CpG 1018.

Table 4: Regulatory Status of Key CpG 1018-Adjuvanted Vaccines

Vaccine Name	Regulatory Agency	Approval Status/Date	Indication	Reference(s)
HEPLISAV-B®	U.S. FDA	Approved (Nov 2017)	Prevention of Hepatitis B (Adults ≥18 yrs)	4
HEPLISAV-B®	EMA	Marketing Authorization	Prevention of Hepatitis B (Adults ≥18 yrs)	16
HEPLISAV-B®	UK MHRA	Marketing Authorization (Feb 2023)	Prevention of Hepatitis B (Adults ≥18 yrs)	15
CORBEVAX™	India DCGI	Emergency Use Approval (Dec 2021)	Prevention of COVID-19	16
VLA2001	UK MHRA	Conditional Marketing Authorization	Prevention of COVID-19	21
VLA2001	EMA (CHMP Opinion)	Positive Opinion	Prevention of COVID-19 (Booster, Adults 18-50 yrs)	21

VII. Comparative Advantages and Clinical Significance of CpG 1018

CpG 1018 offers several distinct advantages over traditional adjuvants and even some other novel adjuvants, contributing to its clinical significance.

A. Enhanced Immunogenicity

A consistent finding across preclinical and clinical studies is the superior immunogenicity conferred by CpG 1018. Compared to alum, CpG 1018 induces significantly higher antibody titers and achieves seroprotection more rapidly.[1] This enhanced potency is particularly valuable in populations that typically exhibit weaker immune responses to vaccination, such as older adults, immunocompromised individuals, and those with chronic conditions like diabetes mellitus.[1] For instance, in HEPLISAV-B® trials, seroprotection rates were notably higher in these groups compared to those receiving an alum-adjuvanted vaccine.[18]

B. Th1-Biased Immune Response

CpG 1018 strongly promotes a Th1-biased immune response, characterized by the production of IFN-γ and the activation of CD8+ cytotoxic T lymphocytes.[3] This type of cellular immunity is crucial for effective clearance of viral infections and intracellular pathogens, an area where traditional Th2-skewing adjuvants like alum are less effective.[3] This targeted immune polarization is a key advantage for vaccines against diseases where cell-mediated immunity is paramount for protection.

C. Potential for Dose Sparing and Simpler Regimens

The enhanced potency provided by CpG 1018 may allow for the use of lower antigen doses (antigen-sparing) or fewer vaccinations to achieve protective immunity.[11] The two-dose, one-month regimen of HEPLISAV-B®, compared to the traditional three-dose, six-month schedule for other hepatitis B vaccines, exemplifies this advantage, potentially improving vaccine compliance and coverage.[18]

D. Safety Profile

CpG 1018 has a well-established safety database derived from extensive clinical trials, most notably the HEPLISAV-B® program, as well as its use in various COVID-19 vaccines and other investigational products.[1] While local injection site reactions (e.g., pain, redness) and transient systemic symptoms (e.g., fatigue, headache) are common, they are generally mild to moderate in severity and self-limiting.[18] The incidence of serious adverse events has been comparable to comparator vaccines.

E. Comparison with Other Adjuvants

When compared to alum, CpG 1018 typically induces higher antibody responses and a distinct Th1-polarized cellular response, whereas alum tends to favor Th2 responses.[1] Studies exploring combinations of CpG 1018 with alum, such as in the CORBEVAX™ and VLA2001 COVID-19 vaccines, suggest a synergistic effect.[11] This strategy potentially combines the depot effect and Th2-inducing properties of alum with the potent TLR9 agonism and Th1-skewing capabilities of CpG 1018, leading to a more comprehensive and robust immune response than either adjuvant might achieve alone. For example, a study on an H7N9 influenza vaccine showed that an Alum/CpG 1018 combination synergistically promoted antibody production and a Th1 bias.[11] The selection of an adjuvant or adjuvant combination is a strategic decision in vaccine design, tailored to the specific antigen and the type of immune response desired for optimal protection. Other adjuvants like MF59 and AS01 also have distinct mechanisms and immune profiles, and direct comparative studies with CpG 1018 across various antigens are valuable for optimizing vaccine formulations. For instance, a study comparing CpG, MF59-like, and Alum adjuvants for a Delta strain inactivated SARS-CoV-2 vaccine in mice showed differences in antibody subtype polarization and T-cell responses, with the CpG-adjuvanted vaccine inducing a higher proportion of IgG2b antibodies, indicative of Th1 immunity.[3]

VIII. Future Directions and Challenges

A. Expansion of Pipeline Applications

The versatility of CpG 1018 is evident in its expanding pipeline. Dynavax continues to advance its development in programs targeting shingles (Z-1018), plague (in collaboration with the DoD), pandemic influenza (H5N1), and Lyme disease.[25] The exploration of CpG 1018 as a monotherapy for Alzheimer's disease represents a particularly innovative avenue, moving beyond traditional vaccine adjuvanting into direct immunomodulation for neurodegenerative disorders.[5]

B. Optimization of CpG 1018 Formulations and Delivery

Further research is likely to focus on optimizing CpG 1018 formulations, potentially through combination with other adjuvants to achieve synergistic effects, as seen with alum in some COVID-19 vaccine candidates.[3] Different delivery systems or co-formulation strategies might also be explored to enhance antigen co-localization with the adjuvant, potentially improving immune responses further or modulating the type of response.

C. Addressing Manufacturing and Supply Chain Considerations

Dynavax has established itself not only as a vaccine developer but also as a commercial supplier of CpG 1018 adjuvant to various partners.[16] Ensuring robust and scalable manufacturing processes and a resilient supply chain will be critical to meet the global demand for CpG 1018, especially as more adjuvanted vaccines progress through clinical development and towards commercialization. This dual role as a developer and supplier diversifies Dynavax's business model. It allows the company to capitalize on its core adjuvant technology through direct product sales (HEPLISAV-B®) and through enabling partnerships for other vaccines. This strategy can mitigate some of the inherent risks of pharmaceutical development, as revenue can be generated from the adjuvant even if some internal vaccine candidates do not reach the market. However, this model is also dependent on the success of its partners, as illustrated by the bad debt expense related to Clover, whose COVID-19 vaccine program faced setbacks.[25]

D. Long-term Safety and Efficacy Monitoring

As with all vaccines and adjuvants, continued long-term safety and efficacy monitoring of HEPLISAV-B® and other CpG 1018-adjuvanted vaccines will be essential as they are deployed more widely in diverse populations. Post-marketing surveillance plays a crucial role in identifying rare adverse events and confirming the durability of protection over time.

IX. Conclusion

CpG 1018 has emerged as a highly effective and versatile TLR9 agonist adjuvant, marking a significant step forward in vaccine technology. Its well-defined mechanism of action, centered on the potent stimulation of Th1-biased innate and adaptive immunity, offers distinct advantages over traditional adjuvants. The successful development and global approval of HEPLISAV-B® have provided robust clinical validation of CpG 1018's ability to enhance immunogenicity, particularly in challenging populations, while maintaining a manageable safety profile.

The application of CpG 1018 extends far beyond hepatitis B prevention, with promising ongoing development programs for vaccines against shingles, plague, pandemic influenza, and Lyme disease. Furthermore, its novel investigation as a standalone immunomodulator for Alzheimer's disease underscores its broad therapeutic potential. As a key enabling technology, CpG 1018 is poised to play an increasingly important role in the development of next-generation vaccines and immunotherapies, contributing significantly to addressing unmet medical needs worldwide. The strategic positioning of Dynavax Technologies as both a vaccine developer and a commercial supplier of CpG 1018 further solidifies the adjuvant's impact on the broader biopharmaceutical landscape.

X. References

4 Dynavax Technologies. (2025). CpG 1018 | toll-like receptor 9 (TLR9) agonist adjuvant.

5 InvivoGen. (n.d.). CpG ODN 1018, VacciGrade™.

1 Campbell, J. D. (2017). Development of the CpG Adjuvant 1018: A Case Study. Methods in Molecular Biology, 1494, 15-27.

7 InvivoGen. (n.d.). ODN 1018 VacciGrade™ Technical Data Sheet.

25 Dynavax Technologies Corporation. (2025, May 6). Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs [Press release].

16 Dynavax Technologies Corporation. (2021, December 28). COVID-19 Vaccine Developed by Biological E Using Dynavax's CpG 1018 Adjuvant Receives India DCGI Approval for Emergency Use [Press release].

14 ConnectRx. (n.d.). Drug overview for HEPLISAV-B (hepatitis b vaccine recombinant/vaccine adjuvant cpg 1018/pf).

18 U.S. Food and Drug Administration. (2024, September). HEPLISAV-B Prescribing Information.

5 InvivoGen. (n.d.). ODN 1018 VacciGrade™ Webpage Detail.

20 Chen, C. Y., et al. (2021). Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. The Lancet Respiratory Medicine, 9(12), 1397-1407. (PMID: 34655522)

41 Vasilev, K., et al. (2024). A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters. Vaccine, 42(X), XXXXXX. (PMID: 39241354)

9 Kang, X., et al. (2023). CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein. Vaccines (Basel), 11(3), 649. (PMCID: PMC10055716)

21 Valneva SE. (2023, February 23). Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001 [Press release].

22 Clover Biopharmaceuticals & Dynavax Technologies Corporation. (2021, June 30). Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate [Press release].

26 BioSpace. (2025, May 6). Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs.

27 Ngram. (n.d.). Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers (NCT05245838).

32 Vax-Before-Travel. (2025, February 21). $30 Million Continues to Fund DoD Plague Vaccine Candidate.

33 JPEO-CBRND. (2021, November 4). DOD Awards Dynavax $22 Million for Plague Vaccine Clinical Trial.

25 Dynavax Technologies Corporation. (2025, May 6). Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs [Press release snippet on influenza].

10 Kang, X., et al. (2024). Overcoming Aging-Associated Poor Influenza Vaccine Responses with CpG 1018 Adjuvant. Proceedings of the 2nd International Electronic Conference on Vaccines.

34 Dynavax Technologies Corporation. (2025, May 7). Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum [Press release snippet on Lyme disease].

42 Vax-Before-Travel. (2025, May 11). Lyme Disease Vaccine Progresses in Phase 3 Clinical Study.

19 Centers for Disease Control and Prevention. (n.d.). GRADE: Hepatitis B Vaccines.

18 U.S. Food and Drug Administration. (2024, September). HEPLISAV-B Prescribing Information (Clinical Trials Experience Section).

28 ClinicalTrials.gov. (2024, June 20). Safety of Simultaneous Vaccination with Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Inactivated Influenza Vaccine (allV4) (Lead) Protocol Snippet (NCT05007041).

35 ClinicalTrials.gov. (n.d.). VLA15 Lyme Disease Vaccine Protocol Snippet (NCT04801420).

5 InvivoGen. (n.d.). ODN 1018 VacciGrade™ Webpage Detail (Pharmacodynamics/Toxicology Focus).

13 Campbell, J. D. (2017). Development of the CpG Adjuvant 1018: A Case Study. Methods in Molecular Biology (Clifton, N.J.), 1494, 15–27. (PMID: 27718183)

29 Dynavax Technologies Corporation. (2025, Q1). Q1 2025 Earnings Call Transcript. Seeking Alpha.

6 Krieg, A. M. (2006). CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology, 24, 209-234. (Conceptual, representative of general CpG ODN knowledge)

17 Valneva SE & Dynavax Technologies Corporation. (2020, September 14). Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated Adjuvanted COVID-19 Vaccine [Press release].

39 Michaeli, D., et al. (2023). Special FDA designations and review pathways: Benefits and risks for drug development and patients. Journal of Cancer Policy, 38, 100458. (PMID: 37962724)

5 InvivoGen. (n.d.). ODN 1018 VacciGrade™ Webpage Detail (Preclinical Grade Properties).

8 Zhang, T., et al. (2024). Screening of CpG oligodeoxynucleotides for porcine epidemic diarrhea virus subunit vaccine and evaluation of the immunoenhancing effect of MF59 and CpG ODNs compound adjuvant. Frontiers in Immunology, 15, 1336239.

3 Li, Y., et al. (2024). Comparative immunogenicity of Delta strain inactivated SARS-CoV-2 vaccines adjuvanted with CpG, MF59-like, and Alum in mice. Virology Journal, 21(1), 15. (PMCID: PMC10819607)

11 Liu, Q., et al. (2023). Combination of Alum and CpG 1018 adjuvants enhances the immunogenicity and protective efficacy of H7N9 whole-virion inactivated vaccine in mice. Vaccines (Basel), 11(9), 1459. (PMCID: PMC10467522)

15 BioSpace. (2024, May 13). FDA Action Alert: Moderna, Dynavax, Ascendis, and BMS.

23 Valneva SE. (2021, July 5). Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st ECCMID [Press release].

5 InvivoGen. (n.d.). ODN 1018 VacciGrade™ Webpage Detail (Safety/Toxicology Focus).

12 Kang, X., et al. (2023). CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein. Vaccines (Basel), 11(3), 649. (PMID: 36992232)

3 Li, Y., et al. (2024). Comparative immunogenicity of Delta strain inactivated SARS-CoV-2 vaccines adjuvanted with CpG, MF59-like, and Alum in mice. Virology Journal, 21(1), 15. 3

2 Wikipedia contributors. (n.d.). Immunologic adjuvant. Wikipedia.

40 PR Newswire. (2025, May 7). Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum [Press release snippet on forward-looking statements].

24 Wilamowski, M., et al. (2023). COVID-19 Vaccines: The Story of Their Development. Vaccines (Basel), 11(10), 1583. (PMCID: PMC10536649)

36 ResearchGate. (2024). Immune modulation to treat Alzheimer's disease. (Conceptual, CpG1018 listed in table for AD)

4 Dynavax Technologies. (2025). CpG 1018 | toll-like receptor 9 (TLR9) agonist adjuvant. 4

5 InvivoGen. (n.d.). CpG ODN 1018, VacciGrade™. 5

25 Dynavax Technologies Corporation. (2025, May 6). Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs [Press release]. 25

16 Dynavax Technologies Corporation. (2021, December 28). COVID-19 Vaccine Developed by Biological E Using Dynavax's CpG 1018 Adjuvant Receives India DCGI Approval for Emergency Use [Press release]. 16

18 U.S. Food and Drug Administration. (2024, September). HEPLISAV-B Prescribing Information. 18

37 ClinicalTrials.gov. (n.d.). Study of CpG 1018 in Early Alzheimer's Disease (NCT05606341). 5

30 ClinicalTrials.gov. (n.d.). Trial to Evaluate Z-1018 Compared to Shingrix® (NCT05245838). 27

38 ClinicalTrials.gov. (n.d.). Study of CpG 1018 in Early Alzheimer's Disease (NCT05606341). 37

31 ClinicalTrials.gov. (n.d.). Trial to Evaluate Z-1018 Compared to Shingrix® (NCT05245838). 30

Works cited

1. Development of the CpG Adjuvant 1018: A Case Study | Request PDF - ResearchGate, accessed May 12, 2025, https://www.researchgate.net/publication/308944635_Development_of_the_CpG_Adjuvant_1018_A_Case_Study
2. Immunologic adjuvant - Wikipedia, accessed May 12, 2025, https://en.wikipedia.org/wiki/Immunologic_adjuvant
3. The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10819607/
4. CpG 1018 | toll-like receptor 9 (TLR9) agonist adjuvant | Dynavax ..., accessed May 12, 2025, https://www.dynavax.com/science/cpg-1018/
5. CpG ODN 1018 Vaccigrade | Sterile TLR9 Ligand - InvivoGen, accessed May 12, 2025, https://www.invivogen.com/odn1018-vaccigrade
6. CpG DNA as a vaccine adjuvant - PMC - PubMed Central, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3108434/
7. ODN 1018 VacciGrade - InvivoGen, accessed May 12, 2025, https://www.invivogen.com/sites/default/files/invivogen/products/files/odn1018_vaccigrade_tds.pdf
8. A novel CpG ODN compound adjuvant enhances immune response to spike subunit vaccines of porcine epidemic diarrhea virus - Frontiers, accessed May 12, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1336239/full
9. CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein - PMC, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10055716/
10. Overcoming Aging-Associated Poor Influenza Vaccine Responses with CpG 1018 Adjuvant, accessed May 12, 2025, https://sciforum.net/paper/view/20403
11. A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10467522/
12. CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/36992232/
13. Development of the CpG Adjuvant 1018: A Case Study - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/27718183/
14. HEPLISAV-B (hepatitis b vaccine recombinant/vaccine adjuvant cpg 1018/pf) - ConnectRx, accessed May 12, 2025, https://www.connectrx.com/product/dynavax-technol/heplisav-b-hepatitis-b-vaccine-recombinant-vaccine-adjuvant-cpg-1018-pf-2/
15. FDA Action Alert: Dynavax, Ascendis and BMS - BioSpace, accessed May 12, 2025, https://www.biospace.com/fda-action-alert-moderna-dynavax-ascendis-and-bms
16. COVID-19 Vaccine Developed by Biological E Using Dynavax's ..., accessed May 12, 2025, https://investors.dynavax.com/news-releases/news-release-details/covid-19-vaccine-developed-biological-e-using-dynavaxs-cpg-1018
17. Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine, accessed May 12, 2025, https://valneva.com/press-release/valneva-and-dynavax-announce-commercial-supply-agreement-for-inactivated-adjuvanted-covid-19-vaccine/
18. Package Insert - HEPLISAV-B - FDA, accessed May 12, 2025, https://www.fda.gov/media/108745/download
19. Grading of Recommendations Assessment, Development and Evaluation (GRADE): HEPLISAV-B | ACIP | CDC, accessed May 12, 2025, https://www.cdc.gov/acip/grade/hepb.html
20. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/34655522/
21. Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001, accessed May 12, 2025, https://valneva.com/press-release/valneva-provides-clinical-and-regulatory-updates-for-its-covid-19-vaccine-vla2001/
22. Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate, accessed May 12, 2025, https://investors.dynavax.com/news-releases/news-release-details/clover-and-dynavax-announce-commercial-supply-agreement-dynavaxs
23. Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases, accessed May 12, 2025, https://valneva.com/wp-content/uploads/2021/07/2021_07_05_VLA_ECCMID_Symposium_PR_EN_Final.pdf
24. COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic - PMC, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10536649/
25. Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs - PR Newswire, accessed May 12, 2025, https://www.prnewswire.com/news-releases/dynavax-reports-first-quarter-2025-financial-results-and-announces-new-pipeline-programs-302447589.html
26. Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs - BioSpace, accessed May 12, 2025, https://www.biospace.com/press-releases/dynavax-reports-first-quarter-2025-financial-results-and-announces-new-pipeline-programs
27. Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers - ngram, accessed May 12, 2025, https://www.ngram.com/trials/NCT05245838
28. 1 Safety of Simultaneous Vaccination with Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Inactivated Influenza Vac - ClinicalTrials.gov, accessed May 12, 2025, https://cdn.clinicaltrials.gov/large-docs/41/NCT05007041/Prot_003.pdf
29. Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript, accessed May 12, 2025, https://seekingalpha.com/article/4782597-dynavax-technologies-corporation-dvax-q1-2025-earnings-call-transcript
30. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT05245838
31. accessed January 1, 1970, https://classic.clinicaltrials.gov/ct2/show/NCT05245838
32. $30 Million Continues to Fund DoD Plague Vaccine Candidate - Vax-Before-Travel, accessed May 12, 2025, https://www.vax-before-travel.com/2025/02/21/30-million-continues-fund-dod-plague-vaccine-candidate
33. DOD Awards Dynavax $22 Million for Plague Vaccine Clinical Trial - JPEO-CBRND, accessed May 12, 2025, https://www.jpeocbrnd.osd.mil/Media/News/Article/2832049/dod-awards-dynavax-22-million-for-plague-vaccine-clinical-trial/
34. Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum - PR Newswire, accessed May 12, 2025, https://www.prnewswire.com/news-releases/dynavax-issues-statement-and-mails-letter-to-stockholders-emphasizing-record-financial-results-and-continued-momentum-302449223.html
35. Phase 2 Study Study Protocol VLA15-221 IND number - ClinicalTrials.gov, accessed May 12, 2025, https://cdn.clinicaltrials.gov/large-docs/20/NCT04801420/Prot_002.pdf
36. (PDF) Immune modulation to treat Alzheimer's disease - ResearchGate, accessed May 12, 2025, https://www.researchgate.net/publication/390341551_Immune_modulation_to_treat_Alzheimer's_disease
37. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT05606341
38. accessed January 1, 1970, https://classic.clinicaltrials.gov/ct2/show/NCT05606341
39. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/37962724/
40. Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) - Public now, accessed May 12, 2025, https://www.publicnow.com/view/F4D0FD43E0F046EA16A8871E21C7D53BE2DEA263
41. A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/39241354/
42. Vaccine News - Vax-Before-Travel, accessed May 12, 2025, https://www.vax-before-travel.com/vaccine-news